Suppr超能文献

血清生物标志物在寡转移前列腺癌患者预后评估中的作用

Contribution of Serum Biomarkers to Prognostic Assessment in Patients With Oligometastatic Prostate Cancer.

作者信息

Nieder Carsten, Dalhaug Astrid, Pawinski Adam

机构信息

Department of Oncology and Palliative Medicine, Nordland Hospital, Bodø, Norway

Department of Clinical Medicine, Faculty of Health Sciences, UiT - The Arctic University of Norway, Tromsø, Norway.

出版信息

In Vivo. 2019 Mar-Apr;33(2):465-468. doi: 10.21873/invivo.11495.

Abstract

BACKGROUND/AIM: The aim of this study was to analyze the prognostic impact of biomarkers, such as serum lactate dehydrogenase (LDH), in patients with oligometastatic castration-resistant prostate cancer, arbitrarily defined as a maximum of five metastatic lesions.

PATIENTS AND METHODS

This was a retrospective single-institution analysis. Overall 34 patients were included, all of whom received first-line docetaxel without ablative local treatment.

RESULTS

Twelve patients (35%) had elevated LDH (≥255 U/l). Their median survival was significantly shorter than that of patients with normal LDH. Due to an interaction with other biomarkers, multivariate Cox regression analysis was performed. The latter showed that serum hemoglobin was the only significant predictor of survival.

CONCLUSION

Correct diagnosis of oligometastatic disease is not trivial, because all radiological modalities are limited by certain thresholds for detection of small metastases. Serum biomarkers may reflect the total burden of malignant disease. However, this relatively small study did not clearly demonstrate that elevation of LDH may be useful for clinical decision-making, e.g. in terms of adding local treatment for all sites of metastatic spread.

摘要

背景/目的:本研究旨在分析生物标志物,如血清乳酸脱氢酶(LDH),对寡转移去势抵抗性前列腺癌患者的预后影响,寡转移定义为最多五个转移病灶。

患者与方法

这是一项单机构回顾性分析。共纳入34例患者,所有患者均接受一线多西他赛治疗,未进行消融性局部治疗。

结果

12例患者(35%)LDH升高(≥255 U/l)。他们的中位生存期明显短于LDH正常的患者。由于与其他生物标志物存在相互作用,因此进行了多变量Cox回归分析。结果显示血清血红蛋白是唯一显著的生存预测指标。

结论

寡转移疾病的正确诊断并非易事,因为所有影像学检查方法都受小转移灶检测的某些阈值限制。血清生物标志物可能反映恶性疾病的总体负担。然而,这项规模相对较小的研究并未明确表明LDH升高可能有助于临床决策,例如在对所有转移扩散部位增加局部治疗方面。

相似文献

4
Serum Prognostic Factors of Androgen-deprivation Therapy Among Japanese Men With Metastatic Prostate Cancer.
Anticancer Res. 2019 Jun;39(6):3191-3195. doi: 10.21873/anticanres.13457.
5
Implications of serum bone turnover markers in prostate cancer patients with bone metastasis.
Urology. 2010 Jun;75(6):1446-51. doi: 10.1016/j.urology.2009.11.049. Epub 2010 Mar 5.
6
Prognostic impact of the neutrophil-to-lymphocyte ratio in men with metastatic castration-resistant prostate cancer.
Clin Genitourin Cancer. 2014 Oct;12(5):317-24. doi: 10.1016/j.clgc.2014.03.005. Epub 2014 Mar 15.
7
The oncological outcomes and risk stratification in docetaxel chemotherapy for castration-resistant prostate cancer.
Jpn J Clin Oncol. 2014 Sep;44(9):860-7. doi: 10.1093/jjco/hyu081. Epub 2014 Jun 20.
8
Relationship between serum markers and volume of liver metastases in castration-resistant prostate cancer.
Cancer Treat Res Commun. 2019;20:100151. doi: 10.1016/j.ctarc.2019.100151. Epub 2019 May 14.
9
Circulating tumor cells as a predictive biomarker in patients with hormone-sensitive prostate cancer.
Clin Genitourin Cancer. 2011 Sep;9(1):31-8. doi: 10.1016/j.clgc.2011.04.001. Epub 2011 Jun 25.
10

引用本文的文献

1
Impact of Body Mass Index on Survival After Docetaxel Chemotherapy for Metastatic Castration-resistant Prostate Cancer.
Cancer Diagn Progn. 2025 Mar 3;5(2):138-145. doi: 10.21873/cdp.10423. eCollection 2025 Mar-Apr.
2
Prognostic and Predictive Biomarkers in Oligometastatic Disease.
Cancer J. 2020 Mar/Apr;26(2):100-107. doi: 10.1097/PPO.0000000000000438.
3
Liquid Biopsy in Oligometastatic Prostate Cancer-A Biologist's Point of View.
Front Oncol. 2019 Aug 14;9:775. doi: 10.3389/fonc.2019.00775. eCollection 2019.

本文引用的文献

1
Recent Advances in Liquid Biopsy in Patients With Castration Resistant Prostate Cancer.
Front Oncol. 2018 Sep 24;8:397. doi: 10.3389/fonc.2018.00397. eCollection 2018.
4
Stereotactic Abative Body Radiotherapy (SABR) for Oligometastatic Prostate Cancer: A Prospective Clinical Trial.
Eur Urol. 2018 Oct;74(4):455-462. doi: 10.1016/j.eururo.2018.06.004. Epub 2018 Jun 29.
5
Liquid Biopsy in Prostate Cancer: Circulating Tumor Cells and Beyond.
Cancer Treat Res. 2018;175:87-104. doi: 10.1007/978-3-319-93339-9_4.
8
Image-guided Stereotactic Body Radiotherapy in Metastatic Prostate Cancer.
Anticancer Res. 2018 May;38(5):3119-3122. doi: 10.21873/anticanres.12572.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验